Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pediatrics. In addition, it provides animal health products. The company was formerly known as Pfizer Laboratories (Bangladesh) Limited and changed its name to Renata Limited in 1993. Renata PLC was incorporated in 1972 and is headquartered in Dhaka, Bangladesh.
Metrics to compare | RNTL | Peers Peers - average of corresponding metrics from companies closely matching RNTL: BXPHARMA, IBNSINA, ACMELAB, SQURPHARMA, BEACONPHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNTLPeersSector |
|---|---|---|---|---|
P/E Ratio | 20.4x | 13.2x | −0.6x | |
PEG Ratio | −0.79 | 0.03 | 0.00 | |
Price/Book | 1.4x | 1.3x | 2.6x | |
Price / LTM Sales | 1.1x | 2.6x | 3.4x | |
Upside (Analyst Target) | 71.1% | 29.0% | 44.9% | |
Fair Value Upside | Unlock | 5.7% | 6.3% | Unlock |